Pearl vs Denti.AI: which dental AI fits your practice?
Key takeaways
- Denti.AI has built voice AI for dentistry since 2018; Pearl added ambient voice in 2026 – so Denti.AI's voice perio and scribe are more mature and refined.
- Both platforms are FDA-cleared for imaging and both now offer scribe and voice perio – so those baselines are even.
- Pearl's edge is imaging depth (the broadest FDA radiograph footprint) plus a revenue-cycle (RCM) product Denti.AI doesn't offer.
- Denti.AI's edge is a mature, voice-first workflow on desktop, web, and iOS – and it brings its own FDA-cleared imaging (Detect + Auto-Chart) too.
Where Denti.AI leads: voice, done right
Pearl started in imaging and added ambient voice in 2026. Denti.AI has been building voice-driven dental AI since 2018 – so on the tools your team uses by voice every day, Denti.AI brings years of refinement, not a first release:
- Denti.AI Voice Perio – assistant-free perio charting in about 5 minutes, with 99% voice accuracy even in a noisy operatory. Its standout feature is an auto-generated, patient-friendly oral-health report that clinicians genuinely love: it helps patients actually see and understand their condition, which is what turns a recommendation into an accepted treatment plan. It also adds DSO management dashboards for multi-location chart audits, plus a standalone mode and low-bandwidth support.
- Denti.AI Scribe – ambient clinical notes in 50+ languages, with 10+ customizable templates including coaching insights and referral letters, plus visit summaries and insurance narratives from one recording. Available on desktop, web, and iOS.
- Denti.AI also brings FDA-cleared imaging of its own – Detect flags caries, bone loss, and pathology on both panoramic and intraoral X-rays and surfaces additional treatment opportunities, while Auto-Chart pushes confirmed findings into the PMS with far fewer clicks.
"Denti.AI Voice Perio has been a game-changer for our practitioners. By streamlining routine charting, it gives our hygienists more time to focus on delivering personalized care." – Cameron Jones, VP of Hygiene Support
Where Pearl leads: imaging, FDA breadth, RCM
Pearl's roots are its advantage here:
- Imaging depth – Second Opinion is a mature radiograph tool with one of the widest FDA clearance footprints in dental AI: 2D intraoral, 3D/CBCT, and panoramic.
- Revenue cycle (RCM) – a dedicated RCM product, which Denti.AI doesn't offer.
Denti.AI offers FDA-cleared imaging too, but Pearl's imaging breadth is deeper and its RCM tooling is something Denti.AI doesn't match. If imaging depth or built-in RCM is your top priority, Pearl has a real claim.
"Second Opinion is so great for me because it's the ideal workflow to diagnose my patients and have an effective communication tool available for speaking to them." – Dr. Ross Nash, via Pearl's testimonials page
Comparison at a glance
*Based on publicly available information as of 2026. The category is moving fast – confirm each vendor's current features and FDA clearances before deciding.
Which should you choose?
Choose Pearl if your decision is imaging-first – the widest FDA radiograph clearances – or if built-in revenue-cycle management is a must-have.
Choose Denti.AI if voice is where your team lives: charting perio and writing notes, backed by years of voice development since 2018, on desktop, web, and iOS. And you're not giving up imaging to get it – Denti.AI Detect is FDA-cleared for both panoramic and intraoral X-rays, and Auto-Chart charts confirmed findings automatically.
The bottom line
Both platforms are FDA-cleared and both now do imaging, scribe, and perio. The difference is heritage. Pearl is the imaging specialist that recently added voice, with deeper imaging breadth and an RCM product. Denti.AI is the voice specialist – since 2018 – that delivers more mature scribe and perio while bringing FDA-cleared imaging of its own.
Want to hear the difference in your own operatory? See how Denti.AI works.
Comparison based on publicly available information as of 2026. Pearl is a trademark of its respective owner; quotes and product details are referenced from public materials to describe differences fairly. Verify current features, quotes, and FDA clearances before publishing.